AstraZeneca PLC
AZNNYSEHealthcare● Active
$185.95
+$4.15(+2.28%)
Market Cap$288.4B
P/E Ratio—
52W High$212.71
52W Low$137.22
AstraZeneca PLC (AZN) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · AZN · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $58.74B | $54.07B | $45.81B | $44.35B | $37.42B |
| Cost of Revenue | $10.63B | $10.21B | $8.27B | $12.39B | $12.44B |
| Gross Profit | $48.11B | $43.87B | $37.54B | $31.96B | $24.98B |
| Gross Margin %(computed) | 81.90% | 81.12% | 81.95% | 72.06% | 66.76% |
| Operating Expenses | |||||
| R&D Expenses | $14.23B | $13.58B | $10.94B | $9.76B | $9.74B |
| G&A Expenses | $19.93B | $19.67B | $17.68B | $17.45B | $15.14B |
| Total Operating Expenses | $34.36B | $33.86B | $29.35B | $28.20B | $23.92B |
| Operating Income | $13.74B | $10.00B | $8.19B | $3.76B | $1.06B |
| Operating Margin %(computed) | 23.40% | 18.50% | 17.88% | 8.47% | 2.82% |
| Interest Income | $0.36B | $0.34B | $0.30B | $0.08B | $0.04B |
| Interest Expense | $1.69B | $1.68B | $1.59B | $1.33B | $1.28B |
| Income Before Tax | $12.40B | $8.69B | $6.90B | $2.50B | ($0.27B) |
| Income Tax Expense | $2.17B | $1.65B | $0.94B | ($0.79B) | ($0.38B) |
| Net Income | $10.26B | $7.04B | $5.96B | $3.29B | $0.11B |
| Net Margin %(computed) | 17.46% | 13.01% | 13.00% | 7.41% | 0.30% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $6.60 | $2.27 | $3.81 | $2.12 | $0.08 |
| Wtd Avg Shares | 1.55B | 1.55B | 1.56B | 1.55B | 1.42B |
| EBITDA | $19.83B | $15.44B | $13.42B | $9.09B | $5.11B |
| EBITDA Margin %(computed) | 33.76% | 28.55% | 29.30% | 20.48% | 13.66% |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · B
Explore more AstraZeneca PLC data
About AstraZeneca PLC (AZN) Income Statement
AstraZeneca PLC (AZN) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, AZN reported revenue of $58.74B, gross profit of $48.11B (gross margin 81.90%), and net income of $10.26B — a net profit margin of 17.46%.
Frequently asked questions
AZN · 4 questionsAstraZeneca PLC (AZN) reported revenue of $58.74B for 2025, up 8.6% year-over-year.
AZN revenueAZN salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08